Pers J O, Berthou C, Porakishvili N, Burdjanadze M, Le Calvez G, Abgrall J F, Lydyard P M, Youinou P, Jamin C
Institut de Synergie des Sciences et de la Santé, Brest University Medical School, Brest, France.
Leukemia. 2002 Jan;16(1):44-52. doi: 10.1038/sj.leu.2402327.
Although B chronic lymphocytic leukemia (B-CLL) is characterized by prolonged survival of CD5(+) B cells in vivo, these cells apoptose spontaneously in vitro. The effect of CD5 ligation on apoptosis was studied in 27 newly diagnosed patients with B-CLL, in relation to the expression of surface IgM (sIgM), CD79b, CD38, CD72 and CD19. B cells from 15 patients (group I) were resistant to anti-CD5-induced apoptosis, whereas apoptosis above spontaneous levels was seen in the remaining 12 studied (group II). Group II was then subdivided on the basis of differences in the time required to reach maximum apoptosis: whilst B cells from seven patients underwent apoptosis by 18 h, those from the remaining five needed 36 h to apoptose. The expression of sIgM, CD5, CD79b and CD38 was higher in group II than group I, suggesting that signaling for apoptosis might operate via CD79, and that CD38 expression was required. As shown by flow cytometry and confirmed by Western blotting, apoptosis was associated with a decrease in the ratios of Bcl-2/Bax and Bcl(XL)/Bax, due to an increase in the level of Bax, but no change in that of Bcl-2. This heterogeneous apoptotic response to CD5 ligation offers an explanation for the incomplete success of anti-CD5 monoclonal therapy, and might help identify patients who would respond to such treatment.
尽管B细胞慢性淋巴细胞白血病(B-CLL)的特征是CD5(+) B细胞在体内长期存活,但这些细胞在体外会自发凋亡。研究了27例新诊断的B-CLL患者中CD5连接对凋亡的影响,并与表面IgM(sIgM)、CD79b、CD38、CD72和CD19的表达相关。15例患者(I组)的B细胞对抗CD5诱导的凋亡具有抗性,而其余12例研究对象(II组)则出现高于自发水平的凋亡。然后根据达到最大凋亡所需时间的差异对II组进行细分:7例患者的B细胞在18小时内发生凋亡,而其余5例患者的B细胞则需要36小时才能凋亡。II组中sIgM、CD5、CD79b和CD38的表达高于I组,这表明凋亡信号可能通过CD79传导,并且需要CD38表达。如流式细胞术所示并经蛋白质印迹法证实,凋亡与Bcl-2/Bax和Bcl(XL)/Bax比值的降低有关,这是由于Bax水平升高,但Bcl-2水平无变化。这种对CD5连接的异质性凋亡反应为抗CD5单克隆治疗不完全成功提供了解释,并可能有助于识别对这种治疗有反应的患者。